Fortress Biotech Stock News

In early March, before the coronavirus pandemic triggered a global economic lockdown, SoftBank Group Corp. founder Masayoshi Son paid tribute to Rajeev Mis

Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that it has priced an underwritten publi

Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will host the Company’s 2020 Annual Meeting of Stockhol

NEW RESIDENTIAL INVESTMENT CORP. BOLSTERS STRONG CAPITAL POSITION AND PROVIDES COMPANY UPDATES

It was another business-as-usual week for patent filings in the District Courts and before the Patent Trial and Appeal Board, with 54 suits and 29 petitions (two post grant reviews and 27 inter partes

WORCESTER, Mass., May 12, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs.

Lindsay Rosenwald became the CEO of Fortress Biotech, Inc. (NASDAQ:FBIO) in 2013. First, this article will compare CEO...

First quarter 2020 product revenue increased 95% year-over-year to $11.9 million NDA for IV tramadol accepted for review by FDA; assigned PDUFA date of October 10, 2020.

WORCESTER, Mass., May 11, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs.

NEW YORK, May 11, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is.

NEW YORK, May 06, 2020 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,.

Bankrupt casual-dining company CraftWorks is willing to sell itself to Fortress Investment Group for $45 million less than the buyer offered earlier, while aiming to reopen as many as 200 restaurants

Stocks Analysis by Zacks Investment Research covering: Celgene Corporation, Bristol-Myers Squibb Company, Corcept Therapeutics Incorporated, Avenue Therapeutics Inc. Read Zacks Investment Research's l